These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. [Beware of the residual curarization!]. Baillard C Ann Fr Anesth Reanim; 2005 Oct; 24(10):1245-6. PubMed ID: 16099133 [No Abstract] [Full Text] [Related]
25. The effect of residual neuromuscular blockade on the speed of reversal with sugammadex. White PF; Tufanogullari B; Sacan O; Pavlin EG; Viegas OJ; Minkowitz HS; Hudson ME Anesth Analg; 2009 Mar; 108(3):846-51. PubMed ID: 19224792 [TBL] [Abstract][Full Text] [Related]
27. Method of intraoperative monitoring of neuromuscular function and residual blockade in the recovery room. Jones KA; Lennon RL; Hosking MP Minn Med; 1992 Jul; 75(7):23-6. PubMed ID: 1357537 [TBL] [Abstract][Full Text] [Related]
28. Neuromuscular block: views from the Western pacific. Futter M; Gin T Anesth Analg; 2010 Jul; 111(1):11-2. PubMed ID: 20576961 [No Abstract] [Full Text] [Related]
29. Residual neuromuscular block: rediscovering the obvious. Brull SJ; Naguib M; Miller RD Anesth Analg; 2008 Jul; 107(1):11-4. PubMed ID: 18635461 [No Abstract] [Full Text] [Related]
31. Sugammadex: a novel agent for the reversal of neuromuscular blockade. Nicholson WT; Sprung J; Jankowski CJ Pharmacotherapy; 2007 Aug; 27(8):1181-8. PubMed ID: 17655516 [TBL] [Abstract][Full Text] [Related]
32. Antagonism of non-depolarising neuromuscular block: current practice. Kopman AF; Eikermann M Anaesthesia; 2009 Mar; 64 Suppl 1():22-30. PubMed ID: 19222428 [TBL] [Abstract][Full Text] [Related]
33. Monitoring neuromuscular blockade in the intensive care unit: the peripheral nerve stimulator. Rowlee SC Heart Lung; 1999; 28(5):352-62; quiz 363-4. PubMed ID: 10486453 [TBL] [Abstract][Full Text] [Related]
34. Extremely prolonged neuromuscular blockade after rocuronium: a case report. Morales Martín AC; Vaquero Roncero LM; Muriel Villoria C Acta Anaesthesiol Scand; 2009 Aug; 53(7):957-9. PubMed ID: 19397500 [TBL] [Abstract][Full Text] [Related]
35. Nondepolarizing Neuromuscular Blocking Agents, Reversal, and Risk of Postoperative Pneumonia. Bulka CM; Terekhov MA; Martin BJ; Dmochowski RR; Hayes RM; Ehrenfeld JM Anesthesiology; 2016 Oct; 125(4):647-55. PubMed ID: 27496656 [TBL] [Abstract][Full Text] [Related]
36. "Neostigmine-resistant curarization". Baraka A Middle East J Anaesthesiol; 2013 Jun; 22(2):131-4. PubMed ID: 24180159 [No Abstract] [Full Text] [Related]
37. Acquired neuromuscular disorders in the intensive care unit. Deem S; Lee CM; Curtis JR Am J Respir Crit Care Med; 2003 Oct; 168(7):735-9. PubMed ID: 14522811 [No Abstract] [Full Text] [Related]
38. Neostigmine product for NMBA reversal approved by FDA. Thompson CA Am J Health Syst Pharm; 2013 Jul; 70(14):1184. PubMed ID: 23820450 [No Abstract] [Full Text] [Related]
39. Delayed reversal of a potentiated rocuronium neuromuscular block. Dubois PE Eur J Anaesthesiol; 2009 Apr; 26(4):350-2. PubMed ID: 19401670 [No Abstract] [Full Text] [Related]